New drug YL242 takes on advanced solid tumors in first human trial
NCT ID NCT07197827
First seen Nov 01, 2025 · Last updated Jun 18, 2026 · Updated 39 times
Summary
This study tests a new drug called YL242, given alone or with other treatments, for adults with advanced solid tumors that have not responded to prior therapy. The main goals are to check safety and see if tumors shrink. About 424 participants will take part in this early-phase trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AUS-101
NOT_YET_RECRUITINGLiverpool, New South Wales, 2170, Australia
Contact
-
AUS-102
RECRUITINGDarlinghurst, Victoria, 2010, Australia
Contact
-
AUS-103
NOT_YET_RECRUITINGHeidelberg, Victoria, 3084, Australia
Contact
-
AUS-104
NOT_YET_RECRUITINGFitzroy, Victoria, 3065, Australia
Contact
-
AUS-105
NOT_YET_RECRUITINGNedlands, Western Australia, 6009, Australia
Contact
-
CN-301
RECRUITINGShanghai, Shanghai Municipality, 200030, China
Contact
-
CN-302
RECRUITINGHangzhou, Zhejiang, 310022, China
Contact
-
CN-303
RECRUITINGHarbin, Heilongjiang, 150081, China
Contact
-
US-201
NOT_YET_RECRUITINGNew Haven, Connecticut, 06519, United States
Contact
-
US-202
RECRUITINGSarasota, Florida, 34232, United States
Contact
-
US-203
NOT_YET_RECRUITINGHouston, Texas, 77030, United States
Contact
-
US-204
NOT_YET_RECRUITINGBoston, Massachusetts, 02215, United States
Contact
-
US-205
RECRUITINGNashville, Tennessee, 37203, United States
Contact
-
US-206
RECRUITINGGrand Rapids, Michigan, 49546, United States
Contact
-
US-207
NOT_YET_RECRUITINGSan Antonio, Texas, 78229, United States
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.